Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT05836753
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Registry
-
NCT05836753
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05836753. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-07 (actual); primary completion 2023-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy
- Acronym
- ESPRIT
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- Sarecycline Tablet
- Intervention (Drug)
- Placebo tablets of Sarecycline tablets
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Neurodawn Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05836753- Content hash
863c60a1f37dd2314291191c8a361745b0be6a16c946ebaba6cc2978b139f6b0